Necrosis on Pre-treatment ^{18}F -FDG PET/CT Predicts Worse Prognosis in Patients With Stage IIIB Non-small Cell Lung Cancer.

Gülrihan Eren (✉ gulrihaneren84@gmail.com)

Recep Tayyip Erdoğan University Hospital, Department of Radiation Oncology <https://orcid.org/0000-0002-3315-3893>

Osman Kupik

Recep Tayyip Erdoğan University Hospital, Department of Nuclear Medicine <https://orcid.org/0000-0001-9473-7940>

Research Article

Keywords: Fluorodeoxyglucose, non-small cell lung cancer, Positron Emission Tomography, necrosis, survival

Posted Date: August 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-806436/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objective

The presence of pathological necrosis in the tumor is known to be a factor indicating worse survival. Our study aimed to define necrosis in staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with stage IIIB non-small-cell lung cancer (NSCLC) to investigate whether this is a poor prognostic marker.

Methodology

To evaluate necrosis on ^{18}F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no FDG uptake on PET and PET/CT fusion images. If SUVmax was less than blood pool SUVmax and showed significantly less attenuation [10 to 30 Hounsfield Units (HU)] than surrounding tissue on low-dose correlative CT with non-intravenous contrast, we defined it as necrotic (PETNECROSIS). We evaluated the relationship of SUVmax, tumor size, and PET_{NECROSIS} with Progression-free survival (PFS) using a cox proportional hazard regression model.

Results

PFS analysis was performed in 16 patients treated with standard chemoradiotherapy (CRT) regimen. Tumor size $\leq 42\text{mm}$ vs $> 42\text{mm}$ ($p = 0.044$, HR: 6.103, 95CI%: 1.053–35.358) and PET_{NECROSIS} presence/absence ($p = 0.027$, HR: 6.719, 95CI%: 1.245–36.264) were independent predictors for PFS. Patients with tumor size $\leq 42\text{mm}$ and PET_{NECROSIS} absence were associated with higher 1-year PFS rate than patients with tumor size $> 42\text{mm}$ and PET_{NECROSIS} presence (86% vs 63.5% $p = 0.005$ and 87.5% vs 29%, $p = 0.001$ respectively).

Conclusion

PET_{NECROSIS} is helpful to distinguish patients who would suffer worse survival in stage IIIB NSCLC.

Introduction

^{18}F -fluorodeoxyglucose (^{18}F FDG) shows glucose metabolism in the tissue. Tumour glucose metabolism in non-small cell lung cancer (NSCLC) has been shown to significantly affect the biological behavior of the tumor and a correlation between the maximum standardized uptake value (SUVmax) and tumor aggressiveness ^[1–3]. Decreased blood flow in the tumor leads to hypoxia ^[4; 5]. Hypoxia is a predictor for radiotherapy (RT) and chemotherapy response. Low oxygen levels are known to reduce the distribution of chemotherapy, and hypoxic tissues are more resistant to RT ^[6; 7].

Tumour necrosis, a common feature of solid tumors, is considered a result of chronic ischemic damage that develops due to rapid tumor growth. Thus, it can be said that the degree of necrosis reflects the level

of intra-tumor hypoxia [8; 9]. The presence of necrosis in surgical material in various types of cancer is associated with poor prognosis, and personalized adjuvant chemotherapy has been recommended in patients with necrosis [10–12]. However, patients with lung cancer are often diagnosed at an inoperable stage. Showing the presence of necrosis on staging ^{18}F -FDG PET/CT may contribute to the management of treatment. However, although the presence of necrosis on staging ^{18}F -FDG PET/CT was shown to be a poor prognostic predictor in patients with sarcoma and lymphoma [13–15], we have found no studies on patients with NSCLC.

The purpose of our study was to investigate if the necrosis as identified on staging ^{18}F FDG PET/CT as a predictor of worse progression-free survival (PFS) in patients with stage IIIB NSCLC.

Methodology

Ethical approval: The Clinical Research Ethics Committee of our institute reviewed and approved this retrospective study (ref. no.40465587-000-63, 2019/50). As this was a retrospective study where the data was de-identified, it was exempt by the institutional review board from the need for informed consent. All procedures performed in studies involving human participants were by the Helsinki declaration.

Patients and Study Design: Patients in whom ^{18}F FDG PET/CT imaging was performed with indications of lung mass/nodule characterization and lung cancer staging between November 2016 and December 2017 were included in the study. NSCLC diagnosis was histopathologically confirmed in all patients. We evaluated PET/CT images of 77 patients with NSCLC. We observed that 27 patients had PET_{NECROSIS}. However, we included only a limited group of patients in the PFS analysis. There are many reasons for this; we did not include 25 patients who refused or interrupted treatment (n= 7), died due to non-disease-related reasons (n=3), and were lost to follow-up (n=15). The remaining 52 patients included a heterogeneous group of patients with different stages and received different treatment protocols. We excluded 13 operable patients who had surgical treatment. Twenty-three of the remaining 39 patients had distant metastases at the time of diagnosis and received different treatment regimens, so we did not include them either. We included 16 patients with stage IIIB NSCLC (AJCC 7th edition) [16]. Seven of these patients had PET_{NECROSIS} (Fig. 1.)

Radiotherapy Technique and Chemotherapy Regimen: All operations were performed using a Varian Trilogy IX linear accelerator (Varian Medical Systems). Intensity-modulated radiotherapy (IMRT) was applied to all patients. Patients were simulated with their arms elevated using a T-bar. Radiotherapy planning computed tomography was performed in spontaneous breathing without the use of the breath-holding technique. Primary tumor and lymph nodes with short axes greater than 1 cm in CT were identified as gross tumor volume (GTV). To cover microscopic extension and create clinical target volume (CTV), delineation was performed by adding 8 mm to the GTV in patients with adenocarcinoma and 6 mm to the GTV in patients with SCC. Considering the tumor movement, internal target volume (ITV) was created by adding an internal margin (IM) to CTV. In the absence of a four-dimensional CT (4D-CT), we

determined a 1 cm value of IM in all directions to encompass a full breathing cycle. Five millimeters were added to the ITV, considering set-up errors to create a planning target volume (PTV) [17]. A median total radiotherapy dose of 68.4 (64.8-71.2) Gy with 1.8 Gy per fraction was given. All the patients received four weekly doses of carboplatin and paclitaxel concurrently with radiotherapy.

Patient Follow-up: PFS was calculated from the date of diagnosis to the date of progression of the disease (new lesion or expansion of the previous existing lesion) or the date of recurrence or death associated with the disease. From the date of diagnosis to the last follow-up, the period was calculated in patients who survived or in whom progression was not observed. Follow-up of the disease was conducted using conventional CT and ^{18}F -FDG PET/CT.

^{18}F -FDG PET/CT Procedures: A PET/CT scanner Biograph mCT (Siemens Healthcare, Erlangen, Germany) was used. After at least 6 hours of fasting, patients with a blood glucose level of <200 mg/dl were administered an FDG injection at an approximate dose of 3.7 MBq/kg. After a median of 63 minutes [min-max 54-79 minutes], imaging was performed in the supine position with arms up. PET imaging was adjusted to 2 minutes per bed position. Low dose CT parameters: voltage, 120 kV; CARE Dose 4D mA tube current; and slice thickness, 5.00 mm.

^{18}F FDG PET/CT Image Analyses: Siemens Healthineers Syngo.via VB30 workstation, MM Oncology, post-processing unit were used for the analyses. All analyses were conducted through consensus by one Nuclear Medicine Specialist (O.K.) with nine years of PET/CT experience and a Radiation Oncologist (G.E.) with ten years of experience. The maximum standardized uptake value normalized to body mass (SUVmax), the tumor size were evaluated.

Tumour Necrosis on ^{18}F -FDG PET/CT Evaluation: We drew a region of interest (ROI) in the area showing visually very low/or no FDG uptake on PET and PET/CT fusion images. If the SUVmax value we measured in ROI was less than the blood pool SUVmax and had significantly lower attenuation from the surrounding tissue in non-intravenous contrast-enhanced low-dose correlative CT, we defined this area as necrotic (PET_{NECROSIS}). On non-intravenous contrast-enhanced low-dose correlative CT, low-attenuation areas were identified with Hounsfield units (HUs) between 10-30 units [14; 18; 19]. Size-adjustable oval-shaped ROIs were used. We drew the ROI with the maximum size from which we would obtain a value of SUVmax lower than the aorta. Lung cavities are gas-filled space, seen as a lucency or low-attenuation area, within pulmonary consolidation, a mass, or a nodule distinguished from PET_{NECROSIS} [20]. PET_{NECROSIS} was decided by consensus of 3 physicians (Fig 2).

Statistical Analysis:

Continuous variables were expressed as median (min-max) and as mean with standard deviation (SD). Variables were compared using either Student's t-test in parametric and Mann-Whitney U tests in non-parametric, depending on the normality of the distribution. Receiver operating characteristic (ROC) statistics of ^{18}F FDG PET/CT parameters were estimated and threshold values providing the optimal

sensitivity and specificity were determined, and those with a $p < 0.05$ were included in the univariate analysis. Univariate and multivariate analyses were performed using the Cox model to assess the relationship between survival and ^{18}F FDG PET/CT parameters. Any variable with $p < 0.2$ in the univariate model was included in the multivariate Cox proportional hazards regression model. The full model included all the variables we studied for multivariate analyses, and the final model was constructed using the backward stepwise procedure. Survival curves for PFS were created using the Kaplan-Meier method. Differences between groups were investigated using the log-rank test. All analyses were performed using SPSS v.22 (SPSS, Inc., Chicago, IL), and two-tailed $p < 0.05$ was considered significant.

Results

Images of 77 patients were evaluated. We observed $\text{PET}_{\text{NECROSIS}}$ in 27 patients. Sixteen patients treated with standard CRT regimen with stage IIIB NSCLC (15 male, one female, 6 had adenocarcinoma, 10 had SCC, mean age 71.81 ± 4.95) were included in the PFS analysis. All variables were independent of histopathological subtype. Patients and tumor characteristics are given in Tables 1. and 2.

By using ROC curve, we determined threshold values for ^{18}F FDG PET/CT parameters according to optimal sensitivity-specificity values. We divided the patients into two groups according to the threshold values and included them in the univariate logistic regression analysis. $\text{SUV}_{\text{max}} \leq 13$ vs > 13 (Sensitivity 83%, specificity 100%, $p = 0.018$, AUC: 0.906, 95CI%: 0.757-1.000), tumor size $\leq 42\text{mm}$ vs $> 42\text{mm}$ (Sensitivity 72%, specificity 80%, $p = 0.017$, AUC: 0.882, 95CI%: 0.715-1.000) were determined.

In univariate Cox proportional hazard regression analysis $\text{SUV}_{\text{max}} \leq 13$ vs > 13 ($p = 0.028$, HR: 10.689, 95CI%: 1.293-88.356), tumor size $\leq 42\text{mm}$ vs $> 42\text{mm}$ ($p = 0.013$, HR: 7.751, 95CI%: 1.527-39.345) and $\text{PET}_{\text{NECROSIS}}$ presence/absence ($p = 0.008$, HR: 8.844, 95CI%: 1.779-43.959) were statistically significant predictors for PFS.

Multivariate Cox proportional hazard regression analysis showed that, tumor size $\leq 42\text{mm}$ vs $> 42\text{mm}$ ($p = 0.044$, HR: 6.103, 95CI%: 1.053-35.358) and $\text{PET}_{\text{NECROSIS}}$ presence/absence ($p = 0.027$, HR: 6.719, 95CI%: 1.245-36.264) were statistically significant independent predictors for PFS. $\text{SUV}_{\text{max}} \leq 13$ vs > 13 was not found independent predictor for PFS ($p = 0.234$, HR: 4.270, 95CI%: 0.391-46.594) (Table 3).

Patients with tumor size $\leq 42\text{mm}$ and $\text{PET}_{\text{NECROSIS}}$ absence were associated with higher 1-year PFS rates than the patients with tumor size $> 42\text{mm}$ and $\text{PET}_{\text{NECROSIS}}$ presence (86% vs. 63.5% $p = 0.005$ and 87.5% vs. 29%, $p = 0.001$ respectively) Fig 3.

Discussion

This study investigated whether necrosis on staging ^{18}F -FDG PET/CT predicted worse PFS in patients with stage IIIB NSCLC. This method has not been investigated previously in this group of patients. We determined the criteria for $\text{PET}_{\text{NECROSIS}}$ to have lower FDG uptake in the tumor than blood pool activity

and have prominent lower attenuation from the surrounding tissue (Attenuation 10-30 HU) non-intravenous contrast-enhanced low-dose correlative CT. Although this method has not been studied in NSCLC patients, similar approaches have been used in different cancers. In a study of patients with diffuse large B cell lymphoma (DLBCL), the periphery of the tumor was hypermetabolic; however, the center which was hypometabolic and had attenuation (10-30 HU) in non-intravenous contrast-enhanced CT and had no increase in HU on intravenous contrast-enhanced CT was described as necrosis. They concluded that ^{18}F FDG PET/CT could accurately detect the presence or absence of necrosis in patients with DLBCL ^[14]. In a study of patients with sarcoma, the relationship between necrosis and survival was investigated. The hypometabolic area in the center of the tumor, which had a hypermetabolic area in the periphery, was evaluated as necrosis if it has corresponded to low attenuation on CT. A threshold value for SUV was not determined; they only defined it as hypometabolic visually. In 39 of 42 patients (92.9%), the presence of necrosis on ^{18}F FDG PET/CT was confirmed histopathologically. MRI results were also highly consistent. Finally, they stated that necrosis observed in ^{18}F FDG PET/CT was a reliable marker and predictive value on patient outcomes ^[13].

In a study of patients with DLBCL, necrosis was defined as areas that had not FDG uptake within FDG avid lymphomatous lesions. No specific visual scale was used. Necrosis on ^{18}F FDG PET/CT was found as a predictor of worse survival ^[15]. Adams et al. investigated the relationship between necrosis on ^{18}F FDG PET/CT and survival in patients with DLBCL. They determined the necrotic area as the areas with low attenuation between 10 and 30HU in non-intravenous contrast-enhanced low dose CT and the areas which did not have increased contrast in intravenous contrast-enhanced full-dose CT (maximum 5HU). Necrosis on PET / CT was found to be a predictor of worse survival ^[18]. In a study conducted with NSCLC patients, it was stated that the proportion of the areas showing FDG uptake at the periphery of the tumor in ^{18}F FDG PET/CT and the areas not showing FDG uptake in the center might indicate the extent of necrosis (either biopsy or surgical resection obtained tumor tissue. The absence or presence and the percentage of necrosis were recorded). They calculated the metabolic/morphological volumes of the tumor. They measured MTV with the threshold of 42% of SUVmax and calculated morphological tumor volume (MoTV) according to lesion definition on CT images. They calculated the ratio of metabolically active volume to global lesion volume (MMVR) by dividing MTV by MoTV, and the ratio was expressed as a percentage. They found that MMVR was inversely proportional to the extent of tumor necrosis ($r = -0.570$, $p = 0.042$). They concluded that metabolically inactive regions might indirectly reflect the degree of necrosis and apoptotic events in the global tumor volume ^[21].

In the studies mentioned above, the areas which showing central hypometabolism in FDG avid tumors were defined as necrotic and supported by CT findings in some of them. Hypometabolism is a relative definition. Relative hypometabolic areas will be monitored in a tumor showing heterogeneous FDG uptake. Which hypometabolic areas should we evaluate for necrosis? For instance, in a lung tumor which heterogeneous FDG uptake with a SUVmax of 25, an area with a SUVmax of 10 is hypometabolic. At the same time, an area with a SUVmax of 5 is also hypometabolic. Which one should we accept as

necrosis? We thought it would be more accurate to determine the upper limit of SUVmax for hypometabolism, which was defined as one of the parameters used to assess necrosis.

Furthermore, we set the blood pool SUVmax for its upper limit. It is already known that tumor FDG uptake should not be higher than blood pool uptake in PET/CT to define it as a complete metabolic response [22]. That is, if the tumor's SUVmax is higher than the blood pool's SUVmax, the presence of residual/viable tumor can be considered. Therefore, we assume that SUVmax of the necrotic area should be at least lower than the SUVmax of the blood pool. In non-intravenous contrast-enhanced low-dose correlative CT, low attenuation areas were defined with Hounsfield units (HUs) between 10-30 units. We determined thresholds for metabolic activity and attenuation in non-intravenous contrast-enhanced low-dose CT, which makes our study differs from the others.

In univariate Cox proportional hazard regression analysis, SUVmax ≤ 13 vs. >13 , tumor size ≤ 42 mm vs. >42 mm, and PET_{NECROSIS} absence-presence were associated with PFS. Multivariate Cox regression analysis showed that SUVmax ≤ 13 vs. >13 was not an independent predictor of PFS. However, studies are claiming that SUV is associated with survival [23-25]. There are also studies stating that SUVmax has no prognostic significance for survival [26-28]. In our study, tumor size >42 mm was an independent predictor for worse survival. In various studies, tumor size is a poor prognostic factor for survival; our findings support the general literature knowledge [29; 30]. We did not include metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in PFS analysis. The primary purpose of our study was to investigate the prognostic value of necrosis identified on staging ^{18}F FDG PET/CT for survival. Since our examination did not consist of many patients, we had to select a limited number of parameters to create a statistical model. We chose to include tumor size, the main morphological parameter, and SUVmax, the most used PET parameter in clinical practice, in the analysis.

In our study, PET_{NECROSIS} presence was found to be an independent predictor of worse survival. One-year PFS was 87.5% vs. 29% patients with PET_{NECROSIS} absence and presence, respectively. As the tumor growth continues, hypoxia is inevitable due to the disruption of the blood supply and exceeding local tissue perfusion, creating necrosis areas [31]. The detection of necrosis in the pathological tumor material has been shown as a poor prognostic factor in many types of cancer [8; 10-12]. Because microscopic necrosis in pathologic specimens is a poor prognostic factor for disease, we are not surprised that the presence of PET_{NECROSIS} is also a poor prognostic factor. However, most patients with lung cancer receive their diagnosis when their disease is inoperable, so we think it may be essential to know the presence of tumor necrosis, which is a poor prognostic factor, before treatment in this large group. Studies investigating the relationship between visual necrosis on FDG PET/CT and survival have shown that necrosis is a marker for poor prognosis in patients with various cancer types. Rakheja et al. found that the presence of necrosis on PET in soft tissue sarcomas was an independent poor prognostic marker [13]. Moo-Kon Song et al. investigated the predictive value of necrosis with ^{18}F FDG PET/CT and conventional CT in patients with DLBCL and found that the presence of necrosis was a poor prognostic factor [14]. Kahle et al. investigated the relationship between prognosis and PET_{NECROSIS} in patients with DLBCL and

found PET_{NECROSIS} as an independent marker for poor prognosis^[15]. Adams et al. showed necrosis on PET/CT as a predictor of worse survival^[18].

Our study has limitations; first of all, our study is single-center and retrospective. Male dominance in the patient group can be explained by the fact that the female population smoked less in this region and had a relatively low incidence of lung cancer. Because of the retrospective nature of the study, histopathological confirmation of necrotic tumor sites was not available. We were able to include 16 patients in the PFS analysis. The number of patients may seem small, but we excluded patients with distant metastases, patients who underwent lung surgery, and patients who did not regularly follow. Thus, we chose to analyze patients who were all at the same stage, received standard CT/CRT, and were regularly followed up. We are already using this method for the first time in this patient group. Since we know that the number of our patients is relatively small, we recommend working with larger patient groups.

In conclusion, we found that necrosis identified on staging ¹⁸F FDG PET/CT was an independent predictor for PFS in patients with stage IIIB NSCLC. PET_{NECROSIS} is helpful to distinguish patients who would suffer worse survival. There is a need for studies with larger groups of patients.

Declarations

Acknowledgment: The authors declare that they have no conflict of interest.

Funding: None.

References

1. Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y, et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). *Radiother Oncol.* 2011; 101:291–297
2. Imamura Y, Azuma K, Kurata S, Hattori S, Sasada T, Kinoshita T, et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. *Lung Cancer* 2011; 71:49–54
3. Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. *Lung Cancer* 2015; 89:115–120
4. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends in molecular medicine.* 2002; 8:S62-S7.
5. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. *J Nucl Med.* 1995; 36:1625–1632

6. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. *Nat Rev Cancer*. 2004; 4:437–447
7. Radiobiology for the Radiologist, 6th ed., Kathryn D. Held. *Radiat Res*. 2006; 166: 816–817.
8. Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O'Byrne KJ. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. *Lung Cancer* 2002; 37:235–240
9. Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P, Zigeuner R. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. *J Urol*. 2006; 176:910–914
10. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. *Br J Cancer*. 2010; 103:1057–1065
11. Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, et al. Tumor necrosis is a new promising prognostic factor in colorectal cancer. *Hum Pathol*. 2010; 41:1749–1757
12. Park SY, Lee H-S, Jang H-J, Lee GK, Chung KY, Zo JI. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. *Ann Thorac Surg*. 2011; 91:1668–1673
13. Rakheja R, Makis W, Tulbah R, Skamene S, Holcroft C, Nahal A, et al. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas. *AJR Am J Roentgenol*. 2013; 201:170–177
14. Song M-K, Chung J-S, Shin D-Y, Lim S-N, Lee G-w, Choi J-C, et al. Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy. *Ann Hematol*. 2017; 96:17–23
15. Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, et al. Tumour necrosis as assessed with 18 F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. *Eur Radiol*. 2019; 29:6018–6028
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010; 17:1471–1474
17. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, et al. Evaluation of microscopic tumor extension in non–small-cell lung cancer for three-dimensional conformal radiotherapy planning. *Int J Radiat Biol*. 2000; 48:1015–1024
18. Adams HJ, De Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC. Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. *Eur J Radiol*. 2015; 84:372–377
19. Hopper K, Diehl L, Cole B, Lynch J, Meilstrup J, McCauslin M. The significance of necrotic mediastinal lymph nodes on CT in patients with newly diagnosed Hodgkin disease. *AJR Am J Roentgenol*. 1990; 155:267–270
20. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008; 246:697–722
21. Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, et al. 18 F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in

- non-small-cell lung cancer. *Eur J Nucl Med Mol Imaging*. 2019; 46:1859–1868
22. Ding Q, Cheng X, Yang L, Zhang Q, Chen J, Li T, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). *J Thorac Dis*. 2014; 6:677
 23. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18 F-FDG PET in nonsurgical patients with non-small cell lung cancer. *Eur J Nucl Med Mol Imaging*. 2012; 39:27–38
 24. Eschmann S, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardized 18 F-FDG uptake value an outcome predictor in patients with stage III non-small-cell lung cancer? *Eur J Nucl Med Mol Imaging*. 2006; 33:263–269
 25. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. *PloS one* 2016; 11:e0146195
 26. Kupik O, Bozkurt M, Asa S, Eren G, Gundogdu H, Arpa M. Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer? *UHOD*. 2020; 30:3.
 27. Vanhove K, Mesotten L, Heylen M, Derwael R, Louis E, Adriaenssens P, et al. Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. *Cancer Treat Res Commun*. 2018; 15:7–12
 28. Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, et al. Prognostic significance of total lesion glycolysis in patients with advanced non-small-cell lung cancer receiving chemotherapy. *Eur J Radiol*. 2012; 81:4179–4184
 29. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan K. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. *Lung Cancer* 2010; 68:398–402
 30. Bonfili P, Di Staso M, Gravina GL, Franzese P, Buonopane S, Soldà F, et al. Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I–II non-small-cell lung cancer. *Lung Cancer* 2010; 67:81–85
 31. Palliative Care E-Book: Core Skills and Clinical Competencies. Emanuel LL, Librach SL. Elsevier Health Sciences. 2011.

Tables

Table 1
Patient characteristics.

Characteristic	N(%)
Sex	
• Female	1 (6.3)
• Male	15 (93.8)
Histology	
• Adenocarcinoma	6 (37.5)
• Squamous cell carcinoma	10 (62.5)
Necrosis identified on FDG PET/CT	
• Presence	7 (43.8)
• Absence	9 (56.3)

Table 2
Tumor characteristics according to histopathological subtype.

Variable	All Patients (n = 16)	Adenocarcinoma (n = 6)	Squamous cell Carcinoma (n = 10)	<i>P*</i> (t/Z)
SUVmax	14.850 ± 5.86	13.350 ± 4.99	15.750 ± 6.40	0.447 (t = 0.783)
Tumor size (mm)	41.94 ± 17.75	33.17 ± 15.64	47.2 ± 17.52	0.130 (t=-1.610)
Age (year)	71.81 ± 4.95	72.17 ± 6.047	71.60 ± 4.52	0.883 (t = 0.214)
Progression free survival (months)	13 (7.7–39)	17.9 (10.9–39)	12.3 (7.7–28.3)	0.051 (Z=-1.954)
(*) No, statistical significance was found between adenocarcinoma and squamous cell carcinoma.				

Table 3
The summary of univariate and multivariate analysis.

Variable	Univariate analysis			Multivariate analysis		
	p	HR	95%CI	p	HR	95%CI
SUVmax ≤ 13 vs > 13	0.028	10.689	1.293–88.356	0.234	4.270	0.391–46.594
Tumor size ≤ 42 mm vs > 42 mm	0.013	7.751	1.527–39.345	0.044	6.103	1.053–35.358
PET _{NECROSIS} presence/absence	0.008	8.844	1.779–43.959	0.027	6.719	1.245–36.264
Abbreviations: HR; hazard ratio, CI; confidence interval.						

Figures

Figure 1

Patient selection diagram

Figure 2

A 64-year-old male with right lung SCC. On PET and fusion images, a wide hypometabolic region at the center of the tumor [SUVmax: 1.02, blue region of interest (ROI)], high FDG uptake at the periphery of the tumor (SUVmax: 21.01, green ROI), and the FDG activity in the arcus aorta (SUVmax: 1.57, red ROI) are shown. On non-intravenous contrast-enhanced low-dose correlative CT, the low-attenuation area (average 19 HU, black ROI) corresponds to the hypometabolic area on PET images. We define this area as PETNECROSIS.

Figure 3

Kaplan–Meier curves of independent prognostic predictors for progression-free survival.